Jane Bell Acquires 233,918 Shares of Mesoblast Limited (ASX:MSB) Stock

Mesoblast Limited (ASX:MSB) insider Jane Bell bought 233,918 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were bought at an average cost of A$0.86 ($0.55) per share, for a total transaction of A$199,999.89 ($129,032.19).

Mesoblast Price Performance

The company has a quick ratio of 1.82, a current ratio of 2.71 and a debt-to-equity ratio of 23.98.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.